Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection
Archives of Microbiology · 2026
DOI: 10.1007/s00203-026-04998-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Microbiology, 2026. Verfasst von Ui-Seok Seo und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chosun University, Gwangju, South Korea. Hauptthemen laut MEDLINE: Enterohemorrhagic Escherichia coli, Escherichia coli Infections, Shiga Toxin. Die Arbeit nennt 83 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
EHEC infection is a toxin-driven systemic disease primarily mediated by the production of Shiga toxin (Stx). Stx is encoded by lysogenic bacteriophages, and SOS-linked prophage induction can increase toxin production in response to environmental or therapeutic stimuli. Once expressed, the toxin rapidly disseminates systemically and binds to cells expressing the globotriaosylceramide (Gb3) receptor. The toxin is then internalized via retrograde intracellular trafficking pathways, ultimately causing inhibition of protein synthesis. These characteristics impose a limited therapeutic window for effective intervention. As a consequence of this pathophysiological framework, current clinical management strategies for EHEC infection remain confined to supportive care. This includes fluid and electrolyte management and organ support, including dialysis and transfusion, in cases complicated by hemolytic uremic syndrome. Antimicrobial therapies that induce the SOS response are mismatched with EHEC pathophysiology and may worsen disease severity by triggering phage activation and toxin expression. The inability to use certain antibiotics in EHEC infection reflects the unique pathophysiological characteristics of the disease. This review considers EHEC infection as a systemic toxigenic disorder and examines Stx-centered pathophysiological constraints. Furthermore, it evaluates the limitations of current therapeutic strategies and examines experimental therapeutic approaches based on the unique pathophysiology of EHEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chosun University, Gwangju, South Korea.
- Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, South Korea.
- College of Pharmacy, Chosun University, Gwangju, South Korea. kcy12@chosun.ac.kr.
- Research Institute of Pharmaceutical Sciences (RIPS), College of Pharmacy, Chosun University, Dong-gu, Gwangju, 61452, Republic of Korea. kcy12@chosun.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Seo, U. S., Park, J. Y., Lee, K. S., & Kim, C. U. (2026). Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection. Archives of Microbiology. https://doi.org/10.1007/s00203-026-04998-0
Vancouver
Seo US, Park JY, Lee KS, Kim CU. Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection. Archives of Microbiology. 2026. doi:10.1007/s00203-026-04998-0
BibTeX
@article{Seo2026,
author = {Seo, Ui-Seok and Park, Jun-Young and Lee, Kyung-Soo and Kim, Chang-Ung},
title = {Shiga toxin-centered pathophysiology defines the therapeutic limits of enterohemorrhagic Escherichia coli infection},
journal = {Archives of Microbiology},
year = {2026},
doi = {10.1007/s00203-026-04998-0}
}
EUVIMED